Result of General Meeting and Total Voting Rights

RNS Number : 2671T

Destiny Pharma PLC

16 March 2023

 

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

Destiny Pharma plc

Result of General Meeting

and

Total Voting Rights

Destiny Pharma plc (AIM: DEST) (the "Company" or "Destiny Pharma"), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that, at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders on a poll.

Accordingly, the Company has raised total gross proceeds of approximately 7.34 million from the Fundraising and has allotted a total of 20,961,956 New Shares. Admission of the Second Placing Shares, the Subscription Shares and the Open Offer Shares, is expected to occur on 17 March 2023.

Following Admission on 17 March 2023, the Company's issued ordinary share capital will comprise 94,459,061 Ordinary Shares, none of which are held in treasury. The above figure of 94,459,061 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

A summary of the votes received for the General Meeting will be made available on the Company's website at  www.destinypharma.com .

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 24 February 2023.

Enquiries:

For further information, please contact: 

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

[phone] 

[e-mail]  

Optimum Strategic Communications 

Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper

[phone]

[e-mail]  

finnCap Ltd  (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

[phone]

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

Stern IR - US

Janhavi Mohite

[phone]

[e-mail]

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Neil Clark
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1 pence each ("Ordinary Shares")
	Identification code	GB00BDHSP575
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 35p 28,571
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	16 March 2023
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Shaun Claydon
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1 pence each ("Ordinary Shares")
	Identification code	GB00BDHSP575
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 35p 14,286
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	16 March 2023
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Nick Rodgers
2.	Reason for the Notification
a)	Position/status	Chairman
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1 pence each ("Ordinary Shares")
	Identification code	GB00BDHSP575
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 35p 28,571
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	16 March 2023
f)	Place of the transaction	London Stock Exchange, AIM Market

 

END

 

 

ROMZZGMFKVRGFZM